- TransCon TLR7/8 Agonist is designed for intratumoral, sustained release of resiquimod with minimal systemic exposure, while inducing a potent anti-tumor response -
Related Post
- PCI Biotech to present at RNA Therapeutics Virtual Conference - January 24th, 2021
- Mydecine Innovations Group Included in First-Ever Psychedelics ETF - January 24th, 2021
- BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema - January 24th, 2021
- Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT... - January 24th, 2021
- aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases - January 24th, 2021
- Report from the Extraordinary General Meeting of Immunicum AB (publ) on 22 January 2021 - January 24th, 2021
- Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule - January 24th, 2021
- Albireo Recognizes International Alagille Syndrome Awareness Day 2021 - January 24th, 2021
- Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform - January 24th, 2021
- Revive Therapeutics Included in First Psychedelic Exchange Traded Fund - January 24th, 2021
- Cambium Networks Corporation Announces Fourth Quarter and Full Year 2020 Reporting Date - January 24th, 2021
- Bioasis Announces Stock Option Grant - January 24th, 2021
- Zealand Pharma announces update to 2020 financial guidance - January 24th, 2021
- Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management - January 24th, 2021
- Blood Sugar Premier – Does This Supplement Really Works? Ingredients & Blood Sugar Premier Reviews by Nuvectramedical - January 24th, 2021
- Medexus Submits Application to List on the Nasdaq - January 22nd, 2021
- XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain - January 22nd, 2021
- Unifor and Aleafia Health enter exclusive agreement to support medical cannabis coverage for members - January 22nd, 2021
- CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange - January 22nd, 2021
- Longboard Pharmaceuticals Appoints Brandi L. Roberts as Chief Financial Officer - January 22nd, 2021
- BetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in Indonesia - January 22nd, 2021
- Auxly Announces Upsized Bought-Deal Public Offering to $17.5 Million - January 22nd, 2021
- Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer - January 22nd, 2021
- Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy - January 22nd, 2021
- DEINOVE strengthens its Business development team to deploy its partnering strategy - January 22nd, 2021
- Hollister Biosciences Inc. Announces an Increase in Private Placement to $6.5 Million - January 22nd, 2021
- MDxHealth Launches Capital Increase and Provides Preliminary 2020 Financial Results - January 22nd, 2021
- MDxHealth Successfully Completes a EUR 25.0 Million (USD 30.4 Million)(1) Capital Increase - January 22nd, 2021
- Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases - January 22nd, 2021
- Bespoke Extracts Announces $100K Investment From CEO and Addition of New Brand Ambassador, UFC Fighter Maryna Moroz - January 22nd, 2021
- Nicox Analyst Coverage Initiated by Edison Investment Research - January 22nd, 2021
- Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation... - January 22nd, 2021
- Immutep Quarterly Activities Report - January 22nd, 2021
- Ulcerative Colitis Phase II Study of GSK2831781 Discontinued - January 22nd, 2021
- ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in... - January 22nd, 2021
- Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel - January 19th, 2021
- Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience - January 19th, 2021
- Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences - January 19th, 2021
- NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member - January 19th, 2021
- Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes - January 19th, 2021
- Bespoke Extracts Increases Conversion Price of Outstanding Discount Convertible Debentures - January 19th, 2021
- Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant - January 19th, 2021
- Novan Provides Enrollment Update and Announces New Corporate Headquarters - January 19th, 2021
- Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer - January 19th, 2021
- Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters - January 19th, 2021
- Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option - January 19th, 2021
- VIRBAC:2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) - January 19th, 2021
- Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference - January 19th, 2021
- Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer - January 19th, 2021
- Agenus to Participate in B. Riley Securities' Oncology Investor Conference - January 19th, 2021
- Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc. - January 19th, 2021
- Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration - January 19th, 2021
- Shockwave Medical to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021 - January 19th, 2021
- Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference - January 19th, 2021
- Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein - January 19th, 2021
- Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure - January 17th, 2021
- Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update - January 17th, 2021
- SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones - January 17th, 2021
- PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology - January 17th, 2021
- Grey Cloak Tech Fuel4Thought™ Migraine Formula Results Published in World Journal of Advanced Research and Reviews - January 17th, 2021
- One World Pharma Receives Colombian Approval for Five THC Strains - January 17th, 2021
- Global Adoption of Biologicals Accelerates as Marrone Bio’s Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in... - January 17th, 2021
- RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing - January 17th, 2021
- Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference - January 17th, 2021
- Ceapro Inc. to Present at NobleCon17 - January 17th, 2021
- Tauriga Sciences Inc. Completes Payment for the Entirety of its Initial Production Run of its Caffeine Infused Version of Tauri-Gum - January 17th, 2021
- DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years - January 17th, 2021
- Dr. Han Myint Appointed as NextCure’s Chief Medical Officer - January 17th, 2021
- AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET - January 17th, 2021
- Global WholeHealth Partners, Corp (GWHP: OTC) Announces the Beginning Research for Saliva COVID 19 SARS 2 Antigen (N+S) Tests - January 17th, 2021
- Qilian International Holding Group Limited Announces Closing of Initial Public Offering - January 17th, 2021
- ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer - January 17th, 2021
- Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant... - January 17th, 2021
- TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference - January 16th, 2021
- Manager’s transactions - January 16th, 2021
- VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC - January 16th, 2021
- MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors - January 16th, 2021
- Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital - January 16th, 2021
- Motus GI Announces European Clearance of Enhanced Pure-Vu® GEN2 System to Harmonize with U.S. Configuration - January 16th, 2021
- Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer - January 16th, 2021
Recent Comments